Sanjay Valvani, 44, reaped unlawful profits of nearly USD 32 million for hedge funds investing in health care securities by insider trading on tips he received from Gordon Johnston, who worked at the Food and Drug Administration and deceptively obtained confidential information.
In parallel actions, the office of US Attorney for the Southern District of New York Preet Bharara also announced criminal charges against Valvani and Johnston.
The charges also carry a maximum fine of USD 5 million.
The Securities and Exchange Commission (SEC) alleges that Johnston concealed his separate role as a hedge fund consultant and obtained confidential information about anticipated FDA approvals for companies to produce enoxaparin, a generic drug that helps prevent formation of blood clots.
More From This Section
Johnston allegedly funneled to Valvani the details of his conversations with FDA personnel, including a close friend he mentored during his time at the agency.
Valvani then traded in advance of public announcements concerning FDA approvals for such companies as Momenta Pharmaceuticals, Watson Pharmaceuticals, and Amphastar Pharmaceuticals.
Ceresney said Valvani and his hedge funds made millions by trading on non-public FDA drug approval information not available to the rest of the stock market.
The SEC further alleges that Valvani in turn tipped fellow hedge fund manager Christopher Plaford, who is charged in a separate complaint with insider trading on this non-public information.